Literature DB >> 15549152

Clinical manifestations, disease course, and complications of adult-onset Still's disease in Taiwan.

Der-Yuan Chen1, Joung-Liang Lan, Tsu-Yi Hsieh, Yi-Hsing Chen.   

Abstract

BACKGROUND AND
PURPOSE: Data on the disease course and ultimate outcome of adult-onset Still's disease (AOSD) are limited. We analyzed the clinical manifestations, disease course, and complications of patients with AOSD in Taiwan.
METHODS: A retrospective cohort design with prospective follow-up was used. Eighty two patients with AOSD diagnosed between 1983 and 2003 were evaluated. Their clinical features and laboratory findings at presentation, disease course, and complications were analyzed.
RESULTS: Fifty nine patients (72%) were female and 55 (67.1%) were aged between 16-35 years at onset. The most common clinical manifestations were fever (100%), articular symptoms (100%), evanescent rash (87%), and sore throat (84%). Dermatographism was noted in 59% of patients. Elevation of erythrocyte sedimentation rate and C-reactive protein, which were significantly correlated with disease activity score (both p < 0.01) occurred in more than 90% of AOSD patients. Elevation of serum ferritin, which was significantly correlated with disease activity score and hepatic enzyme levels, was present in 91% of patients. Polycyclic systemic course was the most common (45%), followed by monocyclic systemic course (34%); only 20% of patients progressed to chronic arthropathy.
CONCLUSIONS: The multisystemic involvement and various patterns of disease course in this series illustrate the heterogenic nature of AOSD. Serum ferritin levels can be used as a marker for monitoring disease activity in AOSD.

Entities:  

Mesh:

Year:  2004        PMID: 15549152

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  10 in total

1.  Therapeutic responses and prognosis in adult-onset Still's disease.

Authors:  Hyoun-Ah Kim; Jun-Mo Sung; Chang-Hee Suh
Journal:  Rheumatol Int       Date:  2011-01-29       Impact factor: 2.631

2.  Clinical features and prognosis of adult-onset Still's disease: 75 cases from China.

Authors:  Zhenzhen Liu; Xiaoju Lv; Guangmin Tang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Successful treatment of refractory adult onset Still's disease with rituximab.

Authors:  K Ahmadi-Simab; P Lamprecht; C Jankowiak; W L Gross
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

4.  Crico-thyroid perichondritis leading to sore throat in patients with active adult-onset Still's disease.

Authors:  Der-Yuan Chen; Howard Haw-Chang Lan; Tsu-Yi Hsieh; Hsin-Hua Chen; Joung-Liang Lan
Journal:  Ann Rheum Dis       Date:  2007-09       Impact factor: 19.103

Review 5.  Urticaria and dermographism in patients with adult-onset Still's disease.

Authors:  Paulo Ricardo Criado; Jozélio Freire de Carvalho; Liliane Akemi Ayabe; Hebert Roberto Clivati Brandt; Ricardo Romiti; Celina W Maruta
Journal:  Rheumatol Int       Date:  2011-07-23       Impact factor: 2.631

Review 6.  Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Ten years of clinical experience with adult onset Still's disease: is the outcome improving?

Authors:  Sukhbir Singh Uppal; Moudhi Al-Mutairi; Sawsan Hayat; Mini Abraham; Anand Malaviya
Journal:  Clin Rheumatol       Date:  2006-11-04       Impact factor: 3.650

Review 8.  New insights on multigenic autoinflammatory diseases.

Authors:  Petros Efthimiou; Olga Petryna; Priscila Nakasato; Apostolos Kontzias
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-03       Impact factor: 3.625

9.  Adult onset Still's disease: a study of 14 cases.

Authors:  S Singh; R Samant; V R Joshi
Journal:  Clin Rheumatol       Date:  2007-08-15       Impact factor: 3.650

Review 10.  Life-threatening complications of adult-onset Still's disease.

Authors:  Petros Efthimiou; Sabeeda Kadavath; Bella Mehta
Journal:  Clin Rheumatol       Date:  2014-01-17       Impact factor: 2.980

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.